The relationship between the incidence of hypomagnesemia and efficacy of anti-EGFR antibodies is controversial; Vincenzi et al. [34] reported that the occurrence of Cmab-induced hypomagnesemia was closely associated with increased tumor response rate and prolonged survival. This evidence concerns the gene EGFR and neoplasm.